277 related articles for article (PubMed ID: 9299173)
1. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis.
Esser P; Heimann K; Bartz-schmidt KU; Fontana A; Schraermeyer U; Thumann G; Weller M
Exp Eye Res; 1997 Sep; 65(3):365-78. PubMed ID: 9299173
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression.
Zhang X; Barile G; Chang S; Hays A; Pachydaki S; Schiff W; Sparrow J
Curr Eye Res; 2005 May; 30(5):395-403. PubMed ID: 16020270
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases.
Robbins SG; Mixon RN; Wilson DJ; Hart CE; Robertson JE; Westra I; Planck SR; Rosenbaum JT
Invest Ophthalmol Vis Sci; 1994 Sep; 35(10):3649-63. PubMed ID: 8088954
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic cell death in proliferative vitreoretinopathy.
Esser P; Bartz-Schmidt KU; Walter P; Kaszli F; Heimann K; Weller M
Ger J Ophthalmol; 1996 Mar; 5(2):73-8. PubMed ID: 8741150
[TBL] [Abstract][Full Text] [Related]
5. [Comparative immunohistochemical studies of epiretinal membranes in proliferative vitreoretinal diseases].
Heidenkummer HP; Kampik A
Fortschr Ophthalmol; 1991; 88(3):219-24. PubMed ID: 1889766
[TBL] [Abstract][Full Text] [Related]
6. Proliferative activity in epiretinal membranes. The use of the monoclonal antibody Ki-67 in proliferative vitreoretinal diseases.
Heidenkummer HP; Kampik A; Petrovski B
Retina; 1992; 12(1):52-8. PubMed ID: 1565872
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
8. Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease.
Spranger J; Meyer-Schwickerath R; Klein M; Schatz H; Pfeiffer A
Exp Clin Endocrinol Diabetes; 1999; 107(1):21-8. PubMed ID: 10077351
[TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical study on vitrectomy specimens of proliferative retinal diseases].
Cao J; Wu L; Zhang H
Zhonghua Yan Ke Za Zhi; 1997 Jul; 33(4):264-7. PubMed ID: 10451957
[TBL] [Abstract][Full Text] [Related]
10. Proliferative activity and immunohistochemical cell differentiation in human epiretinal membranes.
Heidenkummer HP; Kampik A
Ger J Ophthalmol; 1992; 1(3-4):170-5. PubMed ID: 1483131
[TBL] [Abstract][Full Text] [Related]
11. [Transforming growth factor beta in the vitreous of patients with epiretinal proliferation].
Gaudric A; Glacet-Bernard A; Clément G; Falquerho L; Barritault D; Coscas G
Ophtalmologie; 1990; 4(1):51-2. PubMed ID: 2250941
[TBL] [Abstract][Full Text] [Related]
12. Active scatter factor (HGF/SF) in proliferative vitreoretinal disease.
Briggs MC; Grierson I; Hiscott P; Hunt JA
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3085-94. PubMed ID: 10967068
[TBL] [Abstract][Full Text] [Related]
13. TGF-β-stimulated aberrant expression of class III β-tubulin via the ERK signaling pathway in cultured retinal pigment epithelial cells.
Chung EJ; Chun JN; Jung SA; Cho JW; Lee JH
Biochem Biophys Res Commun; 2011 Nov; 415(2):367-72. PubMed ID: 22037456
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy.
Bochaton-Piallat ML; Kapetanios AD; Donati G; Redard M; Gabbiani G; Pournaras CJ
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2336-42. PubMed ID: 10892881
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages.
Kirchhof B; Sorgente N
Dev Ophthalmol; 1989; 16():1-53. PubMed ID: 2676632
[TBL] [Abstract][Full Text] [Related]
16. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
17. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
18. Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Augustin AJ; Spitznas M; Koch F; Grus F; Böker T
Ger J Ophthalmol; 1995 Jan; 4(1):47-51. PubMed ID: 7728110
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases.
Nagineni CN; Samuel W; Nagineni S; Pardhasaradhi K; Wiggert B; Detrick B; Hooks JJ
J Cell Physiol; 2003 Dec; 197(3):453-62. PubMed ID: 14566975
[TBL] [Abstract][Full Text] [Related]
20. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction.
Carrington L; McLeod D; Boulton M
Invest Ophthalmol Vis Sci; 2000 Apr; 41(5):1210-6. PubMed ID: 10752962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
